iMeta | The feasibility of using pathobiome strains as live biotherapeutic products for human use

The feasibility of using pathobiome strains as live biotherapeutic products for human use
Pengfei Jin, Xiong Lin, Wenfeng Xu, Kangning Li, Xiaoxiao Zhao, Sirui Guo, Zinan Zhao, Lujie Jiang, Feng Liao, Longgang Chang, Min Wang, Yanmin Liu, Shaolei Huang, Zhangran Chen, Fusui Ji
First published: 26 May 2024
doi.org/10.100...
Pengfei Jin and Xiong Lin contributed equally to this study.
Graphical Abstract
The evaluation of pathobiome strains should be conducted at the strain level, involving the identification of the functional genes, while considering the impact of ecological niche and drug interactions. The safety, efficacy, and quality management of live biotherapeutic products (LBPs), especially pathobiome strains, have certain peculiarities. Promising development methods include the recombinant LBP and active metabolites.